MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neuroprotective agents"

  • 2023 International Congress

    Quercetin hinders Glial Activation to Alleviate the Cadmium Induced Dopaminergic Alteration via TNFα mediated CAMKIIα/ERK activation

    R. Shukla, V. Khanna, R. Gupta (bahraich, India)

    Objective: The present study has therefore been carried out identify neuroprotective role of quercetin in alleviating the cadmium induced dopaminergic dysfunctions via glial mediated deactivation…
  • 2023 International Congress

    Effects of a small molecule angiotensin IV analog on Huntington’s disease animal model

    R. Wells, A. Azzam, A. Hiller, M. Sardinia (Portland, USA)

    Objective: The present study was designed to test if N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide (AngIV-6a), an angiotensin IV analog, could attenuate 3-nitropropionic acid-induced Huntington’s disease-like symptoms in…
  • 2023 International Congress

    Pharmacological Invivo and invitro potential of resveratrol in experimental rat models of Parkinson’s disease

    R. Kumar, A. Kanojia (Darbhanga, India)

    Objective: Aim of study was to elucidate the pharmacological Invivo and invitro effects and mechanisms of action ofRT in experimental models of PD. Background: The…
  • 2023 International Congress

    Analysis of the therapeutic potential of IkT-148009 in Parkinson’s disease

    M. Werner, R. Rush, T. Kelly, S. Singh, S. Kruger, C. Olanow, A. Mcgarry (Atlanta, USA)

    Objective: To evaluate the therapeutic potential of the selective, brain penetrant c-Abl inhibitor IkT-148009 in mouse models of progressive PD and the safety and tolerability…
  • 2023 International Congress

    Neuroprotective effects of oral consumption of Bifidobacterium lactis and Lactobacillus acidophilus probiotics on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropytide-induced Parkinson’s Disease mouse model

    C. Mo, Y. Qian, Y. Zhang, X. He, Y. Lai, S. Xu, P. Ai, X. Yang, Q. Xiao (Shanghai, China)

    Objective: To explore the effects of probiotics strains Bifidobacterium animalis subsp. lactis (B.lactis) and Lactobacillus acidophilus (L.acidophilus) on the inflammation of gut-brain axis and degeneration…
  • 2023 International Congress

    Potential genetic link between type I diabetes and Parkinson’s disease.

    K. Senkevich, P. Alipour, E. Chernyavskaya, E. Yu, A. Noyce, Z. Gan-Or (Montreal, Canada)

    Objective: To examine whether type 1 diabetes (T1D) is genetically or causally associated with Parkinson’s disease (PD). Background: Previous epidemiological and mendelian randomization studies demonstrated…
  • 2023 International Congress

    Hesperidin ameliorates rotenone-induced Parkinson’s disease in mice via improving neuroinflammation and oxidative stress

    D. Singh (Prayagraj, India)

    Objective: The goal of the present study is to examine the neuroprotective property of hesperidin on rotenone-induced Parkinson's disease in mice. Background: The second most…
  • 2023 International Congress

    The neuroprotective miRNA family hsa-miR-451 has a distinctive pattern of downregulation in neurodegenerative diseases.

    R. Singh, V. Swarup, I. Ahmad, V. Anand, I. Singh, M. Faruq, A. Srivastava (New Delhi, India)

    Objective: 1.Identification of microRNAs from whole blood PBMCs of SCA2 patients by using NGS.    2.To check the exclusivity of miRNAs in SCA2, SCA1,SCA3,SCA12,HD,ALS,PD and MSA-C…
  • 2022 International Congress

    Neuroprotective effects of Ibudilast, a Phosphodiesterase IV inhibitor in mouse model of Parkinson’s disease

    M. Sarswati, A. Gaur (Delhi, India)

    Objective: In the present study, we examined neuroprotective effects, if any, of IBD drug, a  inhibitor of the phosphodiesterase IV in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse…
  • 2022 International Congress

    Exenatide protects iPSC-derived dopaminergic neurons with A53T mutation through restoration of insulin signaling

    D. Athauda, J. Evans, A. Wernick, G. Virdi, M. Choi, K. D'Sa, Z. Shadman, N. Greig, T. Foltynie, S. Gandhi (London, United Kingdom)

    Objective: Here we sought to investigate mechanisms by which insulin resistance affects PD pathogenesis in-vitro, and whether restoration of insulin signaling, using GLP-1 agonist exenatide…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley